# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001308179-26-000144
Filing Date
2026-03-25
Accepted
2026-03-25 16:16:09
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | amrx015308-defa14a.htm | DEFA14A | 9204
2 | GRAPHIC | check.jpg | GRAPHIC | 1441
3 | GRAPHIC | uncheck.jpg | GRAPHIC | 1060
4 | GRAPHIC | logo.jpg | GRAPHIC | 18550
5 | GRAPHIC | notice1.jpg | GRAPHIC | 2369067
6 | GRAPHIC | notice2.jpg | GRAPHIC | 1760048
| Complete submission text file | 0001308179-26-000144.txt |  | 5725476

Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38485 | Film No.: 26792644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)